Gallus Medical Detox Announces Expansion of Services and Name Change
PR.com)-- Gallus Medical Detox, a provider of services to individuals with substance use issues, is pleased to announce that it has expanded services to provide outpatient medication management for those in need of additional taper management after medical detox and those in need of ongoing medication assisted treatment; as well as intensive outpatient (IOP) behavioral services. These services will expand upon existing 24/7 inpatient medical detoxification services that Gallus has provided for nearly 15 years.
To reflect this addition of services, Gallus Medical Detox has changed its name to 'Gallus Detox and Recovery Services.'
Warren Olsen, Chairman and CEO, stated, 'Since our founding in 2011, Gallus has been committed to providing the highest possible care to individuals with substance use disorders. This extension of services is a natural progression in our mission to help these individuals.'
Dr. Ronald Sierzenski, Chief Medical Officer, stated, 'At Gallus, we recognize that substance use is a chronic condition for which many individuals need to constantly work to remain in remission. We want to provide these individuals with services to help maintain their sobriety. For many patients, this may be a combination of inpatient medical detox combined with continued outpatient medical management along with behavioral therapy services like our IOP offering.'
Gallus Medical Detox
James Bryant
Gallus Detox and Recovery provides the highest quality medical detoxification services to patients on both an inpatient and outpatient basis along with IOP services. Gallus operates 24/7, Level 3.7 ASAM in-patient facilities in Arizona, Phoenix detox center, in Colorado at our Denver detox center and in Texas, at our Dallas detox center along with facilities to provide IOP services in these areas.
For additional information, visit www.gallusdetox.com or call (866) 492-7219.
Gallus Detox Centers
James Bryant
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
21-05-2025
- Associated Press
Ventana Education Group Acquires Ultimate Health School; Ena Hull Appointed CEO and President
Manassas, VA May 20, 2025 --( )-- Ventana Education Group LLC is pleased to announce the acquisition of Ultimate Health School, a Virginia-based post-secondary institution specializing in practical nursing and allied health programs. As part of this strategic transition, seasoned education executive Ena Hull has been named President and CEO of the school. Founded in 1999 by Ms. Arangu Ngundam, Ultimate Health School has served the greater Northern Virginia community for over two decades with a mission to provide high-quality healthcare education. Under her leadership, the institution developed a strong reputation for student-centered learning, clinical excellence, and community impact. 'This is more than a business transaction—it's the continuation of a powerful legacy,' said Ena Hull. 'We are committed to preserving the values and quality Ms. Ngundam established while evolving the institution for the next generation of healthcare professionals. I'm honored to take the lead and guide Ultimate Health School into its next era of growth.' As part of the transition, Ms. Ngundam will remain involved in the institution as Founder and Advisor, continuing to support academic leadership and clinical programs. 'I am excited about this next chapter,' said Ms. Ngundam. 'Ena Hull is a dynamic and experienced leader in the field of healthcare education. I am confident she will not only uphold the school's reputation but also elevate it to new heights.' The new ownership plans to expand program offerings, invest in student services, and strengthen local partnerships to meet the increasing demand for trained healthcare professionals across the region. The school will continue operating under its current name with plans for future rebranding as part of its long-term vision. For more information, visit or follow Ultimate Health School on LinkedIn, Instagram, and Facebook. Contact: Office of the President Ultimate Health School Email: [email protected] Website: Contact Information: Ultimate Health School Ena Hull 9494004305 Contact via Email Ena Hull [email protected] Read the full story here: Ventana Education Group Acquires Ultimate Health School; Ena Hull Appointed CEO and President Press Release Distributed by
Associated Press
15-05-2025
- Associated Press
Almora Botanica Debuts in the United States, Introducing Advanced Ayurvedic Skincare and Wellness
New York, NY May 14, 2025 --( )-- Luxury clean-beauty line revolutionizes Ayurveda with clinically proven, plant-based formulas; now shipping nationwide with dedicated U.S. support. Almora Botanica, the award-winning Ayurvedic skincare and wellness brand renowned for its holistic philosophy and science-driven results, proudly announces its arrival in the U.S. market. A localized e-commerce site ( ) and a new fulfillment center in New Jersey now give American consumers fast access to the brand's complete, 99.2% natural-origin collection — each product meticulously crafted to deliver brighter, plumper, visibly healthier skin. Blending centuries-old Ayurvedic wisdom with modern green biotech, Almora Botanica revolutionizes Ayurveda by refining traditional botanicals into ultra-light, scent-neutral textures that absorb almost instantly. The brand was founded by Ravi Prasad, a pioneer in Ayurvedic medicine and global wellness. As the former President, CEO, and Executive Chairman of Himalaya Herbals International, Prasad led the company's expansion into over 50 countries during his 25-year tenure. Central to this innovation is the patented Sapta Complex©, a feather-light blend of seven cold-pressed oils (including amla, moringa, and sesame) that acts as a molecular carrier, driving vitamins, antioxidants, and adaptogens deep into the epidermis. Third-party studies show Sapta Complex-powered formulas boost radiance by 45 % and skin barrier protection by 70% in just six weeks*—all while remaining vegan, cruelty-free, COSMOS-certified, and free from synthetic fragrance. *Data on file; 35 participants, ages 30-55. 'Ayurveda has been my passion and life's devotion,' says Ravi Prasad, Almora Botanica founder and veteran Ayurvedic practitioner. 'With Almora Botanica I set out to craft some of the purest, most effective skincare — uniting time-honored botanicals with contemporary science. We're thrilled to bring this vision to the United States and invite Americans to experience clean, clinically proven solutions that nourish both skin and spirit.' Holistic Performance, Proven by Science Each Almora Botanica formula delivers targeted benefits: the Fine Lines Serum combines Sapta Complex© with centella asiatica to smooth expression lines; Radiance Day Face Oil leverages carrot root extract and sunflower oil for immediate glow; Nourishing Night Face Oil restores lipid balance with borage and sesame seed oil; while the Hydrating & Resilience Face Lotion strengthens the skin barrier with sunflower oil and red algae extract. Availability & Assets Almora Botanica products are available now at and will roll out to select U.S. specialty retailers later this year. High-resolution images, ingredient white papers, and video assets can be downloaded from the press kit (available upon request) About Almora Botanica Founded in 2019 by Ayurvedic expert Ravi Prasad, Almora Botanica is a luxury skincare and wellness brand that unites the ancient wisdom of Ayurveda with modern science. Each formulation is validated by clinical testing and features potent adaptogenic botanicals, delivering high-performance results for a balanced, naturally radiant complexion. Sustainably produced, 100% vegan, and guided by green chemistry principles, Almora Botanica is committed to empowering holistic wellbeing— inside and out. The brand sells at select retailers such as Harrods, John Bell & Croyden, Faces and Isetan, with an eye on US specialty retail expansion. Contact Information: Almora Botanica Christophe Beguel 917-273-0823 Contact via Email Read the full story here: Almora Botanica Debuts in the United States, Introducing Advanced Ayurvedic Skincare and Wellness Press Release Distributed by
Forbes
06-05-2025
- Forbes
Hype Or Hope? Latest Research On GLP-1 Receptor Agonists And Addiction
getty The talk of the town at this year's American Society of Addiction Medicine (ASAM) Annual Conference was GLP-1 receptor agonists (GLP-1 RAs), generally known as medications to treat obesity. Mainstream media appears to mirror this trend as nearly every other radio and television ad seemingly involves a weight loss medication. In addition to treating obesity and type 2 diabetes, GLP-1s have also shown promise with substance use disorders (SUD). Because so many questions exist about safety, efficacy, long-term effects and more, ASAM appropriately invited several scientists and clinicians to present the latest data on the role of GLP-1 RAs in addiction. As a physician, even I'm having trouble keeping track of the assembly-line of anti-obesity medicines. The common ones include semaglutide (Ozempic, Wegovy), liraglutide (Victoza), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity) and exenatide (Byetta). They vary in their duration, formulation and other features. What they share, however, is a common lizard origin—the Gila monster. Origin Story Starts With A Venomous Lizard Copyright 2019 The Associated Press. All rights reserved. Exendin-4, a peptide hormone discovered in 1991 in the venom of the Gila Monster, was structurally similar to the human hormone, glucagon-like peptide-1 (GLP-1), explained Joji Suzuki, MD, FACLP, director of the Division of Addiction Psychiatry at Brigham and Women's Hospital. GLP-1s increased the release of insulin but had an extremely short half-life (1-2 minutes), making them highly unfavorable as a treatment for diabetes. The lizard hormone half-life was nearly 100 times longer (~2.5 hours) which led to more research focusing on increasing half-life, resisting degradation and enhancing binding to the GLP-1 receptor. Since that initial discovery nearly four decades ago, the pace of research and publications on GLP-1 RAs has been nothing short of rapid and robust, according to data shown by Dr. Suzuki. Liraglutide began clinical trial in 2000. Exenatide became the first FDA-approved GLP-1 analog in 2005. Semaglutide was approved by the FDA in 2017 as an injectable treatment for type 2 diabetes under the brand name, Ozempic. Tirzepatide was approved in 2022. That same year, GLP-1 drug sales reached $22 billion. Role In Addiction getty GLP-1 receptors are widely located in the brain, notably in the reward centers. Addictive substances such as nicotine, alcohol and opioids hijack the brain's reward pathway to trigger excess release of dopamine, the 'feel-good' neurotransmitter. Studies show that activation of the GLP-1 receptor in the brain reduces dopamine release from addictive substances such as nicotine and alcohol, leading to less cravings and reinforcement. Researchers who are studying the impact of GLP-1 agonists in addiction are hopeful. 'For the first time in a long time, we actually have the possibility for a whole new class of medications our patients [with addiction] might benefit from,' shared Dr. Suzuki. He continued: 'The exciting part is that GLP-1 RAs might benefit a broad range of addictive behaviors including disordered eating or behavioral addictions.' Nicotine Addiction While randomized control trials (RCT) are few, we do have promising preclinical data showing reduced nicotine withdrawal-induced hyperphagia (excessive hunger) and weight gain with liraglutide. In addition, epidemiological studies have demonstrated that patients with type 2 diabetes (T2D) who used GLP-1 RAs were less likely to be diagnosed with nicotine misuse compared to those who used other medicines for T2D. Less healthcare utilization for tobacco use disorder was also associated with this patient group. Like all medicines, GLP-1 RAs are not benign. Luba Yammine, PhD, associate professor of psychiatry at UTHealth Houston, reminded the packed ballroom that common side effects include gastrointestinal symptoms like nausea, vomiting and diarrhea, as well as acute kidney injury. There's also a higher risk of pancreatitis and medullary thyroid cancer. But Dr. Yammine is optimistic, particularly for people who are addicted to several substances: 'A substantial proportion of people with SUD uses multiple substances. Pending positive outcomes from ongoing and forthcoming RCTs, GLP-1 RA medications may become a pharmacotherapeutic approach for treating polysubstance use.' getty Alcohol Addiction Among all substances, alcohol is by far the most investigated when it comes to GLP-1 RAs. Michael Weaver, MD, professor of psychiatry at UTHealth Houston, highlighted research showing that GLP-1 RAs reduced alcohol consumption in vervet monkeys which are alcohol-preferring primates. Stephanie Weiss, MD, PhD, Assistant Director for Clinical Research, Medication Development Program at NIDA, shared data from the first published clinical trial of GLP-1 RAs in alcohol use disorder: in patients with obesity with a BMI over 30, exenatide reduced heavy drinking days by 23.6% and lowered total alcohol intake. She also shared multiple, ongoing NIDA-funded clinical trials including Semaglutide Therapy for Alcohol Reduction or STAR which is currently recruiting patients. What About Other Drug Addictions? We have limited research on cocaine, according to Dr. Weaver. So far, an experimental (not FDA-approved) GLP-1 agonist compound has been shown to lower cocaine self-administration in rats. We don't have much data for opioids, either. One study revealed that repeated doses of liraglutide ('Victoza') decreased heroin self-administration in rats. Experts are cautious but optimistic. 'Clinical research is necessary. Watch this space,' Dr. Weaver advised the captive audience. getty Ethical Issues Regarding GLP-1 Medications The eruption of GLP-1 RAs has several societal implications including equitable access. Nancy Shenoi, MD, assistant professor of psychiatry at Baylor College of Medicine, pointed out gaps in obesity treatment in low- and middle-income countries and rural areas. She also shared that only four countries offer insurance coverage for obesity treatment: Brazil, Canada, Chile and the U.S. Canada's universal healthcare system and lower prices for diabetes medications enhance accessibility. In addition, the Inflation Reduction Act of 2022 allowed Medicare to negotiate the price of 10 costly medications without a generic; no GLP-1 RA is on this list. Mental health must also be a consideration, stated Dr. Shenois, as some studies suggest that liraglutide and semaglutide may trigger suicidal thoughts, self-injury and depression. Bottom Line Current data on GLP-1 receptor agonists and addiction is certainly promising. Decreased mortality, anti-inflammatory properties and neuroprotective effects can be beneficial in chronic substance use which is associated with neuroinflammation and oxidative stress. But there was a clear consensus among experts at the ASAM conference: more research is needed. 'What we urgently need now are rigorous studies to establish both safety and efficacy of GLP-1 agonists,' reminded Dr. Suzuki. We also need patience. 'Let's not all just jump on the band wagon. Results from clinical trials are years away,' emphasized Dr. Weaver. Lipi Roy, MD, MPH Every presenter also agreed that while we're waiting for the science, let's not forget that we already have anti-addiction medications that work but they're grossly underutilized. Only 1 in 5 people with opioid use disorder and less than 8% of those with alcohol use disorder receive treatment. As an addiction medicine doctor, I cannot underscore this point enough: methadone, buprenorphine, naltrexone and nicotine replacement therapy are safe and effective but unacceptably under-prescribed. Let's maximize existing, lifesaving and transformative medicines for people with addiction while also exploring innovative therapeutic options like GLP-1 receptor agonists.
